· Mainboard · NSE, BSE
Price Band
₹938–988
Lot Size
15 shares
Issue Size
₹1,757 Cr
Min. Investment
₹14,820
Indicative, updates through the day
Cap price plus current GMP: ₹1173 — arithmetic, not a forecast
Symbiotec Pharmalab IPO is a Mainboard issue that listed on NSE, BSE on 1 September 2026. The issue price band is fixed at ₹938–₹988 per equity share with a minimum market lot size of 15 shares, bringing the total issue size to ₹1,757 Cr. At the upper price band, the minimum retail application requires one lot amounting to ₹14,820.
The latest unlisted Grey Market Premium (GMP) for Symbiotec Pharmalab IPO is quoted at ₹185, representing a premium of approximately 18.72% over the upper price band of ₹988. On a simple cap price plus GMP basis, the estimated opening price indicates a listing near ₹1,173, and informal quotes have eased over recent sessions. Please note that GMP is an unregulated sentiment indicator quoted by off-market dealers; it fluctuates based on supply-demand dynamics and does not constitute a guaranteed listing price. For historical accuracy studies, read our research on IPO GMP accuracy, or compare with live GMP quotes for all active IPOs.
As per the latest exchange feeds from BSE and NSE, Symbiotec Pharmalab IPO has been subscribed 75.01x overall — with QIB at 181.2x, NII at 77.53x, bNII at 87.34x, sNII at 57.91x, Retail at 13.56x, Employee at 16.2x, representing over 52,46,066 retail and institutional applications. When the retail category is oversubscribed, SEBI regulations mandate that allotment is determined via an automated computerized lottery where each valid PAN gets one equal chance.
The minimum investment for retail investors is one lot of 15 shares (approx. ₹14,820 at the cut-off price), while the maximum retail bid is capped at 13 lots (under ₹2,00,000). Applications must be submitted using ASBA via Net Banking or the UPI Mandate route through registered stockbrokers (Zerodha, Groww, Angel One, Upstox).
The official registrar appointed for this issue is MUFG Intime India Pvt. Ltd. (formerly Link Intime), with the basis of allotment finalised on 28 August 2026 and listing completed on 1 September 2026. Once declared, you can check your allotment status on our IPO Allotment Checker using your PAN or Application Number. If you are not allotted shares, the ASBA block on your bank funds is automatically released by T+2 day.
Issue Price
₹988
Listed At
₹988
Current Price
₹1097.7
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions. With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations. As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres. Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Symbiotec Pharmalab IPO raises ₹526.20 crore from anchor investors. Symbiotec Pharmalab IPO Anchor bid date is August 21, 2026.
| Category | Shares Offered | % |
|---|---|---|
| QIB | 88,76,516 | 50% |
| − Anchor Investor | 53,25,909 | 0% |
| − QIB (Ex. Anchor) | 35,50,607 | 0% |
| NII (HNI) | 26,62,956 | 15% |
| − bNII > ₹10L | 17,75,304 | 0% |
| − sNII < ₹10L | 8,87,652 | 0% |
| Retail | 62,13,563 | 35% |
| Employee | 33,407 | 0% |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1020 | ₹10,07,760 |
EPS (Pre IPO)
17.82
EPS (Post IPO)
17.39
ROE
9.48%
P/E (Pre IPO)
55.44
P/E (Post IPO)
56.81
Price / Book
5.35
Market Cap
₹6,094Cr.
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Hexagon Nutrition Ltd. | 22.69 | ₹138.87 Cr | |
| Sai Parenteral's Ltd. | 72.19 | ₹408.79 Cr | |
| Corona Remedies Ltd. | 43.47 | ₹655.37 Cr | |
| Rubicon Research Ltd. | 55.75 | ₹1,377.50 Cr | |
| Amanta Healthcare Ltd. | 34.59 | ₹126.00 Cr | |
| Anlon Healthcare Ltd. | 17.67 | ₹121.03 Cr |
Symbiotec Pharmalab Ltd. Address
MUFG Intime India Pvt. Ltd. (formerly Link Intime)